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JohOBJECTIVES The purpose of this study was to investigate the predictive values of baseline and changes in cystatin C
(CysC) and its derived equations for short-term adverse outcomes and the effect of nesiritide therapy on CysC in
acute decompensated heart failure (ADHF).
BACKGROUND Newer renal biomarkers or their derived estimates of renal function have demonstrated long-term
prognostic value in chronic heart failure.
METHODS CysC levels were measured in sequential plasma samples from 811 subjects with ADHF who were enrolled in
the ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) biomarker sub-study
(randomized to nesiritide therapy vs. placebo), and followed for all-cause death (180 days) and recurrent hospital stay
(30 days).
RESULTS Median CysC levels were 1.49 (interquartile range [IQR]: 1.20 to 1.96) mg/l at baseline, 1.56 (IQR: 1.28 to 2.13)
mg/l at 48 to 72 h, and 1.58 (IQR: 1.24 to 2.11) mg/l at 30 days. Higher baseline (but not follow-up) CysC levels were
associated with increased risk of 30-day adverse events and less improvement in dyspnea after 24 h as well as 180-day
mortality, although not incremental to blood urea nitrogen. Worsening renal function (deﬁned as a 0.3 mg/l increase in
CysC) occurred in 161 of 701 (23%) patients, but it was not predictive of adverse events. Changes in CysC levels were
similar between the nesiritide and placebo groups.
CONCLUSIONS Our ﬁndings conﬁrmed the prognostic value of baseline CysC levels in the setting of ADHF. However,
worsening renal function based on CysC rise was not predictive of adverse events. Nesiritide did not worsen renal
function compared with placebo. (J Am Coll Cardiol HF 2015;3:40–9) © 2015 by the American College of Cardiology
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AB BR E V I A T I O N S
AND ACRONYM S
ADHF = acute decompensated
heart failure
BUN = blood urea nitrogen
CKD-EPI = Chronic Kidney
Disease Epidemiology
Collaboration
CysC = cystatin C
GFR = glomerular
ﬁltration rate
WRF = worsening
renal function
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41R enal insufﬁciency and worsening renal func-tion (WRF) are prevalent in acute decom-pensated heart failure (ADHF), and they
often coincide with diuretic unresponsiveness and
inability to relieve congestion (1,2). This situation
translates into worse outcomes associated with
renal insufﬁciency and WRF. Hence, preservation
of renal function is an important therapeutic goal
in the treatment of acute heart failure. Although
tubular functions are likely important as well, renal
function has traditionally been quantiﬁed by its
glomerular ﬁltration rate (GFR). As the most
frequently used marker of GFR, serum creatinine
and its derived equations have thus become the
mainstays of renal assessment in guiding manage-
ment and risk stratiﬁcation. However, because of
variable production, dietary inﬂuence, dependence
on muscle mass, and tubular secretion, the recip-
rocal relationship of serum creatinine with GFR
has well-known limitations.
Cystatin C (CysC) is a small 13-kDa cysteine prote-
ase inhibitor that is ubiquitously produced at a fairly
constant rate in all nucleated cells. It is freely ﬁltered
and neither secreted nor reabsorbed into the blood-
stream. The general consensus has been that CysC is
a more sensitive marker of early renal insufﬁciency
(3,4). Several studies have suggested the prognostic
role of baseline CysC levels in long-term adverse
outcomes in the setting of ADHF (5,6), as well as in
chronic stable heart failure (7–10). Meanwhile, newer
estimates of GFR have also used CysC to achieve
better prognostication in various stable clinical set-
tings (8,11–13). As a result, there has been a strong
emphasis on using CysC and CysC-derived equations
in clinical practice, including the ADHF setting, in
which renal dysfunction is common. However, pro-
spective evaluations of clinical utility of serial CysC
measurements or CysC-derived GFR estimates and
their responses to therapeutic interventions have
been less well established.
The ASCEND-HF (Acute Study of Clinical Effec-
tiveness of Nesiritide in Decompensated Heart Fail-
ure; NCT00475852) biomarker substudy creates a
unique opportunity to investigate these questionsJohnson & Johnson. Drs. Gottlieb, Voors, Butler, and Massie are consultants
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Manuscript received April 17, 2014; revised manuscript received June 23, 20(14). Herein, we test the hypothesis that
elevated CysC (and its derived GFR estimate)
is associated with poor short- and
intermediate-term prognosis. In particular,
we aim to describe the prevalence and time
course of CysC elevations in acute heart fail-
ure, the relationship of prevalent and inci-
dent CysC elevation to dyspnea response, 30-
day clinical outcomes, and nesiritide
response.
METHODS
STUDY POPULATION. The design and pri-
mary results of the main ASCEND-HF study have been
described elsewhere (14,15). Brieﬂy, ASCEND-HF was
a multicenter randomized, double-blind, placebo-
controlled trial of nesiritide, a recombinant B-type
natriuretic peptide with vasodilatory properties,
compared with placebo in 7,141 patients admitted to
the hospital with ADHF. Patients with clinical evi-
dence of acute coronary syndrome or baseline
troponin level >5 times the upper reference limit at
the local clinical laboratory were excluded from the
trial. The biomarker sub-study enrolled 811 subjects
who underwent serial venous blood sampling at
baseline, 48 to 72 h following initiation, and at 30-day
follow-up visit as previously described (16). Eighty-
ﬁve percent of patients in the biomarkers sub-study
were enrolled in North America. Blood samples were
collected in ethylenediaminetetraacetic acid plasma,
immediately centrifuged, and stored at 80F for
subsequent analysis at core laboratory.
CYSTATIN C MEASUREMENT. Plasma CysC level was
determined with a particle-enhanced immunoturbi-
dimetric immunoassay on the Architect ci8200 plat-
form (Abbott Laboratories, Abbott Park, Illinois).
Brieﬂy, latex particles are coated with anti-human
CysC antibody and agglutinate with CysC present
in the patients’ sample. The result is a change in
absorbance that is proportional to the amount of CysC
present in the sample. The analytic range spans
0.05 mg/l to the highest calibration point. Intra-
assay and interassay coefﬁcients are 3.1% and 6%,to and on the advisory board of Johnson & Johnson.
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42respectively. Baseline, 24-h, and end-of-treatment
serum creatinine levels were measured at local labo-
ratories. Estimated glomerular ﬁltration rates (eGFR)
were estimated by the 4-variable Modiﬁcation of Diet
in Renal Disease (MDRD) equation and by arbitrarily
determining subjects as having either preserved
(eGFR $60 ml/min/1.73 m2) or impaired (eGFR <60
ml/min/1.73 m2) renal function at baseline. When
quantitatively comparing the prognosis of renal
indices among different models, we used the Chronic
Kidney Disease Epidemiology Collaboration (CKD-
EPI) formula for serum creatinine, CysC, and both
biomarkers (17). Blood urea nitrogen (BUN) values
measured at local laboratory were collected as part of
the ASCEND-HF study.
CLINICAL ENDPOINTS. Co-primary endpoints were
improvement in dyspnea at 6 or 24 h as measured by
a 7-point Likert scale and the composite endpoint of
hospital stay for heart failure or death at 30 days.
For analysis of the relationship between CysC and
dyspnea response, dyspnea was dichotomized as
moderately or markedly improved at 6 and 24 h
relative to the time of randomization. The composite
of persistent or worsening heart failure and death
from any cause was a secondary endpoint. Events
were adjudicated up to 180 days.
STATISTICAL ANALYSES. Clinical characteristics
were presented as percentage (%) for categorical
variables, mean  SD for normally distributed con-
tinuous variables, and median (interquartile range
[IQR]) for non-normally distributed continuous vari-
ables. The Cochran-Armitage test was used to test
for trend in baseline characteristics in increasing
tertiles of baseline CysC. Levels of CysC and changes
therein were compared between patients receiving
nesiritide and placebo by using Wilcoxon rank sum
test or Student t test. A 2-sided probability value
of <0.05 was considered statistically signiﬁcant. The
association between CysC and outcomes was per-
formed using both univariate and multivariate logis-
tic regression analysis (30 days mortality) or Cox
proportional hazards analysis (for length of stay and
180 day mortality). CysC was slightly skewed. Both
log-normal transformation and nontransformation
were tested, and the results had no difference. Re-
sults here are presented by nontransformation. To
identify the association between baseline CysC and
dyspnea improvement at 6 or 24 h, logistic regression
was used. Odds ratio (OR) and hazard ratio (HR)
represent the risk per unit increase in CysC. The
clinical endpoints of interest were: 1) 30-day mortal-
ity; 2) the composite of 30-day mortality and recur-
rent hospital stay for heart failure; 3) 180-daymortality; 4) dyspnea improvement at 6 and 24 h;
5) death or worsening HF before discharge; and
6) length of stay for the index hospital stay. We con-
ﬁrmed that the proportional hazards assumption
was met for the Cox regressions for length of stay and
180-day mortality. When comparing the prognostic
value between creatinine and CysC, we use the area
under the curve (c-statistic) from receiver operator
characteristic curve. For the multivariable analysis,
we adjusted the covariates identiﬁed from the overall
ASCEND-HF study population (Online Table 1). Death
at 180 days was evaluated by Kaplan-Meier survival
analysis. Differences between groups were calculated
with the log-rank test. The Net reclassiﬁcation in-
dex (NRI) for evaluating the improvement in predic-
tion performance gained by adding renal indices to
base covariates model was calculated according
to the Pencina method (18). All statistical analyses
were performed using SAS software version 9.2
(SAS Institute, Cary, North Carolina).
RESULTS
STUDY POPULATION. The ASCEND-HF biomarker
sub-study population was similar to the overall study
population with the exception that 88% of patients
were enrolled in North America (43% in the main
trial). The median CysC level at baseline was 1.49
(IQR: 1.20 to 1.96) mg/l. Table 1 illustrates the baseline
characteristics of our sub-study cohort, stratiﬁed by
baseline CysC levels. Subjects with higher CysC levels
were more likely to be older, with history of coronary
artery disease, diabetes mellitus, and atrial ﬁbril-
lation, and with higher left ventricular ejection
fraction.
SERIAL CYSTATIN C LEVELS. Of the 811 patients with
baseline CysC levels, 701 and 598 had available 48- to
72-h and 30-day levels, respectively. As compared
with baseline, CysC was higher at 48 to 72 h (1.56
[IQR: 1.28 to 2.13] mg/l, p < 0.01 compared with
baseline) and at 30 days (1.58 [IQR: 1.24 to 2.11] mg/l,
p < 0.01 compared with baseline). Figure 1 demon-
strates that no difference in CysC evolution occurred
as a function of treatment randomization (placebo vs.
nesiritide). Both placebo and nesiritide groups
demonstrated similar increases in CysC levels from
baseline to 48 to 72 h (þ0.14  0.30 mg/l vs. þ0.11 
0.33 mg/l, p ¼ 0.47), as well as from baseline to
30 days (þ0.12  0.41 mg/l vs. þ0.15  0.43 mg/l,
p ¼ 0.17). The ratios of follow-up to baseline CysC
were higher in the placebo group than in the nesiri-
tide group at 48 to 72 h (1.78  0.6 vs. 1.74  0.7,
p ¼ 0.31) and at 30 days (1.78  0.7 vs. 1.70  0.7,
p ¼ 0.08), but their differences did not reach
TABLE 1 Baseline Characteristics
Total
(N ¼ 811)
Cystatin C (mg/l)
p Value*
Tertile 1
0.58–1.28
(N ¼ 268)
Tertile 2
1.29–1.80
(N ¼ 275)
Tertile 3
1.81–4.20
(N ¼ 268)
Age (yrs) 65.75  14.94 58.83  15.72 66.47  14.23 71.93  11.62 <0.01
Male (%) 562 (69.30) 191 (72.27) 196 (71.27) 175 (65.30) 0.13
Race (white, %) 550 (67.82) 157 (58.58) 192 (69.82) 201 (75.00) <0.01
Systolic BP (mm Hg) 127.12  20.03 127.24  20.82 126.04  18.44 128.11  20.79 0.61
Heart rate (beats/min) 80.26  16.47 84.71  16.46 81.11  16.15 74.94  15.33 <0.01
Atrial ﬁbrillation (%) 338 (41.68) 91 (33.96) 116 (42.18) 131 (48.88) 0.001
Hypertension (%) 631 (77.81) 194 (72.39) 215 (78.18) 222 (82.84) 0.004
BUN (mg/dl) 10.31  6.08 6.84  2.93 8.97  3.89 15.12  7.14 <0.01
Creatinine (mmol/l) 128.54  52.08 96.85  23.65 114.40  31.00 174.75  57.75 <0.01
Cystatin C (mg/l) 1.64  0.61 1.07  0.16 1.51  0.15 2.35  0.47 <0.01
Sodium (mEq/l) 138.63  3.87 138.20  3.93 138.41  3.74 139.29  3.87 <0.01
LVEF (%) 26 (20, 40) 25 (15, 35) 27 (20, 40) 30 (20, 45) <0.01
Time from presentation
to randomization (h)
18.03 (8.08, 22.60) 17.69 (7.69, 22.42) 17.58 (8.85, 22.55) 18.54 (7.97, 22.93) 0.38
Ischemic etiology (%) 493 (60.79) 128 (47.76) 162 (58.91) 203 (75.75) <0.01
Beta-blockers (%) 613 (75.59) 194 (72.39) 207 (75.27) 212 (79.10) 0.07
ACEI or ARB (%) 524 (64.61) 179 (66.79) 183 (66.55) 162 (60.45) 0.13
MRA (%) 198 (24.41) 68 (25.37) 76 (27.64) 54 (20.15) 0.16
Values are mean  SD, n (%), or median (Q1, Q3). *p value from test of trend.
ACEI ¼ angiotensin converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; BP ¼ blood pressure; BUN ¼ blood urea nitrogen; LVEF ¼ left ventricular ejection
fraction; MRA ¼ mineralocorticoid receptor antagonist.
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43statistical signiﬁcance. There were good correlations
between CysC and creatinine levels at their respec-
tive time points (baseline r ¼ 0.70; 48 to 72 h
r ¼ 0.6 with 24-h creatinine and r ¼ 0.69 with
end-of-treatment creatinine).
ASSOCIATION OF BASELINE AND FOLLOW-UP
CYSTATIN C AND OUTCOMES. Figure 2 shows
Kaplan-Meier curves for all-cause death after 180
days according to baseline as well as 48- to 72-h CysC
tertiles. A total of 25 (3.1%) and 95 (11.9%) deaths
occurred at 30 days and 180 days of follow-up,
respectively. The composite of death or recurrent
hospital stay for heart failure at 30 days occurred in
98 patients (12.3%). Table 2 illustrates the associa-
tions among baseline CysC levels, dyspnea scores,
and clinical outcomes. In univariate analysis, higher
baseline CysC levels were associated with more
adverse events (all p values < 0.01), longer length of
stay, and less improvement in dyspnea score at 24 h
(p ¼ 0.03). Apart from dyspnea improvement at 24 h,
all these associations persisted after multivariable
adjustment (adjusted model 1). However, when BUN
and creatinine values were included in these models
(adjusted model 2), none of the signiﬁcant asso-
ciations persisted. Furthermore, higher follow-up
(48 to 72 h) CysC levels conferred higher risk of
adverse outcomes in the unadjusted model, andhigher follow-up (48 to 72 h) CysC levels were not
associated with more adverse events after adjust-
ments even without BUN and creatinine included
(Table 2). There were also no statistically signiﬁcant
differences between the 180-day death endpoint us-
ing baseline CysC and changes in creatinine (log-
transformed, c-statistics 0.72 vs. 0.73, p ¼ 0.63). We
further evaluated the incremental prognostic value
of CysC when considering baseline estimates of renal
function and observed that the prognostic value of
CysC was negated in a similar fashion whether it was
BUN or estimates of GFR using CKD-EPI equations
that used creatinine, CysC, and both (Table 3). Among
the various renal indices, the highest AUC and NRI
achieved were adding BUN to ASCEND-HF covariates
to CysC. In addition, higher CysC levels at 30 days
predicted 180-day all-cause mortality (tertiles 1 vs. 2
vs. 3: 3.5% vs. 8.2% vs. 12.6%, p ¼ 0.002), and even
after adjusting for baseline BUN, baseline CysC, age,
systolic blood pressure (adjusted HR: 2.07; 95%
conﬁdence interval [CI]: 1.17 to 3.64, p ¼ 0.01).
ASSOCIATION OF CHANGE IN CYSTATIN C AND
OUTCOMES. To assess the clinical signiﬁcance of
CysC changes, outcomes were compared between
patients with a $0.3 mg/l increase in CysC (signifying
WRF) and patients without such an increase. After
48 to 72 h, 161 of 701 patients (23.0%) experienced
FIGURE 1 Cystatin C Levels Stratiﬁed by Treatment Groups (Placebo vs. Nesiritide)
at Baseline, 48 to 72 h, and 30 Days After Randomization
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44WRF. Interestingly, changes in CysC correlated only
modestly with changes in creatinine from baseline to
24 h (r ¼ 0.25) or to end of trial (r ¼ 0.38). Outcomes
were not different between those with or without
WRF (Table 4, Figure 3), or when stratiﬁed according
to an increase or decrease in CysC of $0.3 mg/l versus
unchanged (Online Table 2). Higher changes in CysC
at 30 days did not predict 180-day all-cause mortality
when adjusted for baseline BUN, baseline CysC,
age, and systolic blood pressure (HR: 1.43, 95% CI:
0.76 to 2.67, p ¼ 0.27). We further observed that
patients with abnormal ranges of baseline CysC
levels (>1.4 mg/l) had higher 30-day and 180-day
mortality rates. Interestingly, lowering CysC levels
from abnormal range at baseline back to the normal
range at 48 to 72 h was associated with lower 30-day
or 180-day mortality. For changes from baseline
to 30 days, only those patients with persistently
elevated CysC demonstrated the highest mortality
risk at the 180-day visit. In contrast, differences
between groups regarding hospital stay for heart
failure were not as consistent (Online Table 3).
Patients with dynamic renal function (increase or
decrease in CysC of $0.3 mg/l) were also compared
with patients who had stable renal function, and no
difference in the 180 day all-cause death rate was
observed (Figure 3). Furthermore, there were no sta-
tistically signiﬁcant differences between the nesiri-
tide versus placebo groups in patients with high
baseline CysC or low baseline CysC (stratiﬁed at the
median CysC level) for the development of WRF(either deﬁned as change in CysC $0.3 mg/l at 72 h or
at 30 days), urine volume at 24 h, or any clinical
events. As expected, patients with higher baseline
CysC experienced less urine output at 24 h after
randomization when compared with patients with
lower CysC (within the nesiritide group: median 2.4 l
vs. 2.9 l, p ¼ 0.002; within the placebo group: median
2.4 l vs. 3.0 l, p ¼ 0.029). However, higher baseline
CysC levels have no impact on the incidence of WRF
compared with low baseline CysC at 30 days (23.1%
vs. 26.6%, p ¼ 0.322), even though a higher incidence
of WRF was observed at 48 to 72 h (19.3% vs. 26.6%,
p ¼ 0.021) (Figure 4).
DISCUSSION
The key ﬁndings of this study are as follows: 1)
baseline CysC is a strong predictor of adverse events
in patients admitted with ADHF; 2) the predictive
ability of CysC (or its GFR estimates) is independent
of many other risk factors but not of other standard
measures of renal function such as BUN; 3) changes in
CysC during treatment or follow-up (48- to 72-h level)
do not seem to have predictive ability for intermedi-
ate or long-term all-cause mortality; and 4) nesiritide
has no signiﬁcantly favorable or detrimental effect on
renal function as judged by serial CysC levels. Based
on our ﬁndings using a more sensitive marker of
glomerular ﬁltration, we conclude that CysC or CysC-
derived GFR estimates do not provide incremental
clinical insights into clinical course of ADHF beyond
traditional renal indices such as BUN, they do not
predict responses to nesiritide therapy.
Several studies performed in the last decade
convincingly showed the importance of renal func-
tion as a predictor of adverse events in patients with
(AD)HF (2). As a result, preservation of renal function
has become a separate goal during treatment of acute
heart failure, going from the premise that renal-
sparing therapies will translate into overall better
outcomes. Although the kidney has a tubular and
endocrinologic function as well, its function is almost
invariably judged by quantifying GFR. Traditionally,
serum creatinine and derived equations are used for
this purpose, although several reports have pointed
toward CysC as an improved marker of GFR, in pa-
tients both with and without heart failure (8,17).
Recent derivations of CysC-based equations have
further provided evidence to support the notion that
these improved estimates of GFR can provide more
precise and accurate prediction of adverse events
in populations with chronic heart failure (13,17,19).
Although higher baseline CysC portends poorer short-
term and long-term prognosis and identiﬁes a
FIGURE 2 Kaplan-Meier Analysis of 180-Day All-Cause Death Stratiﬁed by Cystatin C Tertiles
(A) Baseline cystatin C levels. (B) Cystatin C tertiles at 48 to 72 h.
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45subgroup of patients with less robust diuretic re-
sponses to medical therapy, we did not observe in-
crements above and beyond traditional renal indices
in the setting of ADHF. There may be several poten-
tial explanations. First, derivations of CysC and GFR
equations that use CysC or creatinine were based on
measurements in stable patients with chronic kidney
disease in whom glomerular ﬁltration is the primary
determinant of renal function. In the setting of ADHF,
dysregulated central and renal hemodynamics as a
result of volume overload or following aggressive
decongestion may confound such derivations, asTABLE 2 Baseline and Follow-Up (48- to 72-h) Cystatin C levels and
Endpoint
Unadjus
OR/HR
Baseline Cystatin C
Death at 30 days 2.46
Death/recurrent hospital stay at 30 days 1.61
Death at 180 days 2.07
Improved dyspnea at 6 h 0.86
Improved dyspnea at 24 h 0.70
Death or worsening heart failure prior to discharge 2.09
Length of stay‡* 0.74
Length of stay‡* (high vs. low) 1.88
Follow-up (48- to 72-h) Cystatin C
Death at 30 days 2.63
Death/recurrent hospital stay at 30 days 1.65
Death at 180 days 2.07
Length of stay‡* 0.81
Length of stay‡* (high vs. low) 1.63
*Adjusted model 1 ¼ covariates derived from overall ASCEND-HF population excluding B
population including BUN and creatinine. ‡For length of stay, numerically lower hazard
ASCEND-HF ¼ Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Hsome investigators have suggested (20). Second, in-
ﬂammatory and endothelial cell activation in response
to venous congestion (21,22) may also generate coun-
terregulatory CysC production above and beyond
myocardial dysfunction (6). The ﬁnding that BUN,
rather than CysC or any GFR estimates, achieved
the greatest incremental prognostic value in a
head-to-head comparison beyond standard clinical
predictors of adverse clinical outcomes may directly
challenge the broad acceptance of these newer mea-
surements to predict the clinical course of renal
dysfunction in ADHF.Intermediate- and Long-Term Outcomes
ted Adjusted Model 1* Adjusted Model 2†
p Value OR/HR p Value OR/HR p Value
<0.01 2.14 0.01 1.44 0.42
<0.01 1.74 <0.01 0.81 0.49
<0.01 1.70 <0.01 0.86 0.59
0.26 0.96 0.84 0.98 0.93
0.03 0.72 0.16 0.77 0.40
<0.01 2.28 <0.01 1.04 0.93
<0.01 0.75 <0.01 0.85 0.10
<0.01 1.86 <0.01 1.45 0.08
<0.01 2.91 0.13 2.25 0.26
<0.01 1.31 0.45 1.27 0.53
<0.01 1.37 0.33 1.30 0.43
<0.01 1.05 0.68 1.02 0.91
<0.01 0.93 0.79 1.00 0.99
UN and creatinine. †Adjusted model 2 ¼ covariates derived from overall ASCEND-HF
ratio equates to high risk for increased length of stay.
eart Failure; BUN ¼ blood urea nitrogen; HR ¼ hazard ratio; OR ¼ odds ratio.
TABLE 4 Outcomes for Patients With or Without Worsening
Renal Function ($0.3 mg/l Rise in Cystatin C at 48–72 h)
Endpoint
Cystatin C Increase $0.3 mg/l at 48–72 h
No (n ¼ 540) Yes (n ¼ 161) p value
Death at 30 days 13 (2.4%) 6 (3.7%) 0.41
Death or recurrent hospital
stay at 30 days
64 (12.1%) 21 (13.0%) 0.76
Death at 180 days 61 (11.4%) 18 (11.5%) 0.97
Values are n (%).
TABLE 3 Prognostic Value of Adverse Outcomes According to Model Adjusted for Renal Indices
Incremental Adjustment to Model* Cystatin C BUN GFRCysC GFRCr GFRCr/CysC
Death at 30 days OR 2.14 (1.17–3.90)† 1.06 (1.01–1.12)† 0.97 (0.94–1.00) 0.97 (0.95–0.99)† 0.97 (0.94–0.99)†
AUC 0.77 0.76 0.77 0.76 0.77
NRI 55.9%‡ 44.8%‡ 28.4%‡ 41.3%‡ 33.0%‡
Death/recurrent hospital
stay at 30 days
OR 1.74 (1.22–2.46)‡ 1.03 (0.98–1.07) 0.98 (0.97–0.99)‡ 0.98 (0.97–0.99)‡ 0.98 (0.97–0.99)‡
AUC 0.66 0.68 0.65 0.67 0.67
NRI 26.6%‡ 44.1%‡ 23.7%‡ 35.0%‡ 29.9%‡
Death or worsening heart
failure before discharge
OR 2.28 (1.37–3.79)‡ 1.06 (1.00–1.12) 0.97 (0.95–0.99)‡ 0.97 (0.95–0.99)‡ 0.97 (0.95–0.99)‡
AUC 0.74 0.74 0.73 0.72 0.74
NRI 58.5%‡ 60.9%‡ 33.9%‡ 46.8%‡ 56.1%‡
Death at 180 days HR 1.70 (1.28–2.27)‡ 2.49 (1.70–3.64)‡ 0.98 (0.97–0.99)‡ 0.98 (0.97–0.99)‡ 0.98 (0.97–0.99)‡
AUC 0.71 0.72 0.71 0.71 0.72
NRI 32.3%‡ 44.5%‡ 29.8%‡ 40.2%‡ 39.4%‡
*Base model ¼ covariates derived from overall ASCEND-HF population excluding BUN and creatinine. †p < 0.05. ‡p < 0.01.
ASCEND-HF¼ Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure; AUC¼ area under the curve; BUN¼ blood urea nitrogen; Cr¼ creatinine; CysC¼ cystatin C;
GFR ¼ glomerular ﬁltration rate; NRI ¼ net reclassiﬁcation index; OR, odds ratio.
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46The clinical utility of single time-point versus
serial measurements of renal indices has been
debated in recent years, after its initial endorsements
as an important prognostic determinant. Lassus et al.
(23) previously reported their ﬁndings in 292 subjects
of the FINN-AKVA (Finnish Acute Heart Failure)
study with available baseline and 48-h CysC levels.
The investigators proposed a 0.3 mg/l increase
in CysC as a sensitive and clinically meaningful
threshold for the prediction of adverse events (3).
There are some important differences in the study
populations: patients in the FINN-AKVA study were
on average 10 years older and were more likely to be
female and with history of hypertension. In addition,
they had a higher left ventricular ejection fraction
and were included even if they were admitted with
an acute coronary syndrome. Our data, containing
more than twice as many patients with careful
endpoint adjudication and largely from North Amer-
ican sites, could not conﬁrm the predictive ability of
this deﬁnition of WRF. The absence of an association
between WRF and adverse outcomes is likely not
caused by the biomarker or the exact cut-off point
itself, but it may reside in the way WRF is deﬁned
or other extrarenal factors. Some studies identiﬁed
subgroups of patients experiencing WRF with either
improved (hemoconcentration) or impaired (tubular
injury) survival (24,25). Clearly, the notion that WRF
measured by changes in serum creatinine may re-
present detrimental end-organ injury and damage
remains controversial. Nevertheless, we did not ob-
serve any difference in outcomes even when we
characterized our study population with respect to
stable versus dynamic renal function (Figure 3B).
These observations did not clarify the complexityof renal insufﬁciency related to ADHF therapy, but
it is at best reassuring to note that baseline CysC
did not inﬂuence long-term changes in CysC. Further
investigations to examine the pathophysiologic un-
derpinnings of such ﬂuctuations in serum creatinine
levels in this patient population are warranted.
Our current analysis also consolidates the safety
proﬁle of nesiritide, thereby challenging initial re-
ports of the detrimental effect of this drug on renal
function, as highlighted in previous reports. These
ﬁndings are concordant with recent reports of similar
urine output between nesiritide and placebo in the
overall ASCEND-HF study cohort (26). In general,
CysC levels were somewhat higher after 48 to 72 h
and 30 days compared with that of baseline, but these
changes were not signiﬁcantly different between
those treated with placebo and those receiving
nesiritide. This ﬁnding is in spite of a higher
incidence of symptomatic and asymptomatic hypo-
tension (a potential WRF-inducing factor) in the
nesiritide-treated group (14). However, these ﬁndings
are in contrast with recent reports of fewer changes
in CysC with administration of serelaxin versus
FIGURE 3 Kaplan-Meier Curves for 180-Day All-Cause Mortality Comparing Patients With or Without Short-Term (48- to 72-h)
Changes in Renal Function
(A) Worsening renal function ($0.3 mg/l increase in cystatin C at 48 to 72 h). (B) Dynamic renal function ($0.3 mg/l increase or decrease
in cystatin C at 48 to 72 h).
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47placebo in the RELAX-AHF (Relaxin for the Treatment
of Acute Heart Failure) study, in which serelaxin
was associated with less rise in CysC compared with
placebo (27).
It is important to highlight in the ASCEND-HF
biomarker sub-study cohort that short-term changes
in CysC in our relatively large cohort did not confer
any long-term prognostic value. The recentlyFIGURE 4 Comparison Between High and Low Baseline CysC Levels
and Worsening Renal Function
(A) Urine output at 24 h. (B) Worsening renal function. Cystatin C (CysC
renal function deﬁned by changes in CysC levels from baseline to 48 topublished ROSE (Renal Optimization Evaluation
Strategies) study used changes in serial CysC levels as
1 of the 2 co-primary endpoints to evaluate potential
incremental beneﬁt of 2 intravenous interventions
(low-dose dopamine and low-dose nesiritide) over
standard therapy in ADHF (28). Although the neutral
results based on the primary endpoint still tracked
concordantly with the 90-day clinical outcomeon Renal Function Deﬁned by Urine Output at 24 h
) levels stratiﬁed according to median level of 1.49 mg/l. Worsening
72 h as well as to 30 days.
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48measures, the serial CysC comparisons were practi-
cally equivalent, whereas the outcome measures
trended nonsigniﬁcantly, particularly in the
nesiritide-treated group. Hence, whether changes in
serial CysC levels can serve as reliable surrogates for
subsequent long-term adverse outcomes remained to
be determined.
STUDY LIMITATIONS. The most obvious limitation
of this study is that there is no direct measurement
of GFR. However, good evidence exists, even in
patients with heart failure, that CysC reﬂects GFR
accurately. Other major limitations include the
absence of available follow-up creatinine and BUN
values taken at exactly the same time points as
the CysC draws (48 to 72 h and 30 days of research
blood draw analyzed in core laboratory versus clinical
blood draw for creatinine levels at baseline, 24 h, and
at the end of treatment) and the absence of urine
output data beyond the ﬁrst 24 h. In our biomarker
substudy, there were only 4 incidents of “orthostatic
hypotension” and 19 incidents (18 patients) of “hy-
potension.” Coupled with the small number of pa-
tients with changes in CysC over time, there were
too few events to determine the relationshipbetween baseline and changes in CysC and hypoten-
sion (known adverse effect of nesiritide). We also did
not have the data to separate the different contri-
butors to renal insufﬁciency in the setting of de-
compensated heart failure from pharmacotherapy.
Nevertheless, the ﬁndings are reassuring regarding
the renal safety of nesiritide, and they further suggest
that pre-existing or persistently elevated renal bio-
markers such as CysC provide more prognostic in-
sights than their transient changes during aggressive
decongestive therapy.
CONCLUSIONS
Higher admission levels of CysC, but not short-term
rise in CysC, are associated with adverse events
in ADHF. Changes in CysC levels were not different
between nesiritide-treated and placebo-treated
groups.
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